AstraZeneca and Daiichi Sankyo’s ENHERTU showed objective response rates of 49% and 56% with 5.4mg/kg and 6.4mg/kg doses respectively in primary analysis
ENHERTU provided a median.
A recent study at the University of Jyväskylä (Finland) compared the gut microbiota and gut-derived metabolites between healthy controls and individuals with fatty liver.
AstraZeneca: Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers privataaffarer.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from privataaffarer.se Daily Mail and Mail on Sunday newspapers.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed .
/PRNewswire/ The "Cell Line and Membrane Market By Products, By Source, By Type, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031".